SMS Lifesciences Reports December 2024 Results Highlighting Growth Amid Liquidity Concerns

SMS Lifesciences India, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a notable shift in the company's evaluation, with the score adjusting to 13 from 21 over the past three months.
The financial data reveals several positive aspects for SMS Lifesciences. The Profit Before Tax (PBT), excluding other income, reached Rs 6.86 crore, reflecting a significant year-on-year growth of 112.38%. Similarly, the Profit After Tax (PAT) stood at Rs 5.47 crore, marking a year-on-year increase of 27.2%. Additionally, the company's debt-equity ratio has improved, recorded at its lowest of 0.49 times over the last five half-yearly periods, indicating a reduction in borrowing relative to equity capital.

Conversely, there are areas of concern. The Debtors Turnover Ratio has declined to 4.68 times, the lowest in the last five half-yearly periods, suggesting a slowdown in the pace of settling debts. Furthermore, cash and cash equivalents have decreased to Rs 1.19 crore, the lowest in the last six half-yearly periods, indicating challenges in short-term liquidity.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.